Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism

Pharmaceutical Research

Volumn 28, Issue 8, 2011, Pages 1931-1938

  Wang, Yow Ming C ^a   Sloey, Bethlyn ^a   Wong, Teresa ^a   Khandelwal, Prerna ^a   Melara, Rebeca ^a   Sun, Yu Nien ^a  

^a AMGEN INC   (United States)

Author keywords

clearance mechanism; nonlinear pathway; pharmacokinetics; rodents; romiplostim

Indexed keywords

ROMIPLOSTIM;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CATABOLISM; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; KNOCKOUT MOUSE; MALE; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; RODENT; SINGLE DRUG DOSE; SPLENECTOMY; THROMBOCYTE; THROMBOCYTOPENIA;

ANIMALS; BIOMIMETIC MATERIALS; BLOOD PLATELETS; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEPHRECTOMY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; SPLENECTOMY; THROMBOPOIETIN;

EID: 79961165922     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0420-y     Document Type: Article

References (20)

1. K Cohen-Solal N Debili W Vainchenker F Wendling 1997 Thrombopoietin (Mpl-ligand) and the regulation of platelet production Thromb Haemost 78 37 41 9198124 1:CAS:528:DyaK2sXktFemurs%3D (Pubitemid 27289947)
2. Brown AS EJ, Martin JF. Megakaryocytopoiesis: the megakaryocyte/platelet haemostatic axis. In: Franz von Bruchhausen UW, editor. Platelets and Their Factors: Springer; 1 edition (July 15, 1997) 1997. p. 3-26.
3. Jackson C, Arnold JT, Pestina TI, Stenberg PE. Megakaryocyte Biology. In: Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D, editors. Thromobopoiesis and Thrombopoietins; Molecular, Cellular, Preclinical, and Clinical Biology. Totowa, New Jersey.: Humana Press; 1997. p. 3-40.
4. Hall MP, Gegg C, Walker K, Spahr C, Ortiz R, Patel V, et al. Ligand-Binding Mass Spectrometry to Study Biotransformation of Fusion Protein Drugs and Guide Immunoassay Development: Strategic Approach and Application to Peptibodies Targeting the Thrombopoietin Receptor. AAPS J.
5. G Molineux A Newland 2010 Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside Br J Haematol 150 9 20 20298251 1:CAS:528:DC%2BC3cXpsVGrur8%3D
6. DE Mager WJ Jusko 2001 General pharmacokinetic model for drugs exhibiting target-mediated drug disposition J Pharmacokinet Pharmacodyn 28 507 32 11999290 10.1023/A:1014414520282 1:CAS:528:DC%2BD38XjsFSrtro%3D (Pubitemid 34289541)
7. B Wang JL Nichol JT Sullivan 2004 Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand Clin Pharmacol Ther 76 628 38 15592334 10.1016/j.clpt.2004.08.010 1:CAS:528:DC%2BD2cXhtVKlt7vJ (Pubitemid 39601552)
8. J Li Y Xia DJ Kuter 1999 Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics Br J Haematol 106 345 56 10460590 10.1046/j.1365-2141.1999. 01571.x 1:CAS:528:DyaK1MXlvVOhsrc%3D (Pubitemid 29450656)
9. DJ Kuter RD Rosenberg 1995 The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit Blood 85 2720 30 7742532 1:CAS:528: DyaK2MXls1Sru70%3D
10. C Engel M Loeffler H Franke S Schmitz 1999 Endogenous thrombopoietin serum levels during multicycle chemotherapy Br J Haematol 105 832 8 10354155 10.1046/j.1365-2141.1999.01459.x 1:STN:280:DyaK1M3ot1enug%3D%3D (Pubitemid 29277049)
11. AE Geddis HM Linden K Kaushansky 2002 Thrombopoietin: a pan-hematopoietic cytokine Cytokine Growth Factor Rev 13 61 73 11750880 10.1016/S1359-6101(01) 00030-2 1:CAS:528:DC%2BD3MXpt1ahurs%3D (Pubitemid 34436962)
12. AV Hoffbrand 2005 Oral iron chelators in the treatment of hematologic diseases Clin Adv Hematol Oncol 3 536 8 16167033 (Pubitemid 41558145)
13. Stoelting RK, Miller Ronald D. Basics of anesthesia 5th ed. Churchill Livingstone: Elsevier; 2007. p. 338.
14. B Chen K Jerger JM Frechet FC Szoka Jr 2009 The influence of polymer topology on pharmacokinetics: differences between cyclic and linear PEGylated poly(acrylic acid) comb polymers J Control Release 140 203 9 19465070 10.1016/j.jconrel.2009.05.021 1:CAS:528:DC%2BD1MXhsVyju7nN
15. CP Hansen JP Goetze F Stadil JF Rehfeld 1999 Excretion of progastrin products in human urine Am J Physiol 276 G985 92 10198343 1:CAS:528: DyaK1MXislCksbY%3D
16. MR Ujhelyi S Robert 1995 Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity Clin Pharmacokinet 28 483 93 7656506 10.2165/00003088-199528060-00006 1:STN:280:DyaK2MzosFaqsA%3D%3D
17. JW Proksch WB Gentry SM Owens 1998 Pharmacokinetic mechanisms for obtaining high renal coelimination of phencyclidine and a monoclonal antiphencyclidine antigen-binding fragment of immunoglobulin G in the rat J Pharmacol Exp Ther 287 616 24 9808688 1:CAS:528:DyaK1cXnsVertL0%3D (Pubitemid 29133661)
18. T Behr W Becker E Hannappel DM Goldenberg F Wolf 1995 Targeting of liver metastases of colorectal cancer with IgG, F(ab')2, and Fab' anti- carcinoembryonic antigen antibodies labeled with 99mTc: the role of metabolism and kinetics Cancer Res 55 5777s 85s 7493346 1:CAS:528:DyaK2MXps12htb8%3D
19. SA McQuarrie RP Baum A Niesen R Madiyalakan W Korz TR Sykes, et al. 1997 Pharmacokinetics and radiation dosimetry of 99Tcm-labelled monoclonal antibody B43.13 in ovarian cancer patients Nucl Med Commun 18 878 86 9352556 10.1097/00006231-199709000-00013 1:CAS:528:DyaK2sXntVGisbY%3D (Pubitemid 27444601)
20. Wang YM, Krzyzanski W, Doshi S, Xiao JJ, Perez-Ruixo JJ, Chow AT. Pharmacodynamics-Mediated Drug Disposition (PDMDD) and Precursor Pool Lifespan Model for Single Dose of Romiplostim in Healthy Subjects. AAPS J.